AR053865A1 - Composiciones y metodos para el tratamiento de neoplasmas - Google Patents

Composiciones y metodos para el tratamiento de neoplasmas

Info

Publication number
AR053865A1
AR053865A1 ARP060101829A ARP060101829A AR053865A1 AR 053865 A1 AR053865 A1 AR 053865A1 AR P060101829 A ARP060101829 A AR P060101829A AR P060101829 A ARP060101829 A AR P060101829A AR 053865 A1 AR053865 A1 AR 053865A1
Authority
AR
Argentina
Prior art keywords
treatment
methods
compositions
neoplasms
neoplasm
Prior art date
Application number
ARP060101829A
Other languages
English (en)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of AR053865A1 publication Critical patent/AR053865A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composiciones que incluyen dos, tres o más agentes utiles en el tratamiento de un paciente con neoplasma, métodos para el tratamiento a un paciente con un neoplasma tales como cáncer (cáncer de cerebro), entre otros equipamientos que incluyen uno, dos, tres, o más agentes utiles en el tratamiento de cáncer, como así también métodos para la identificacion de combinaciones de compuestos potencialmente utiles en el tratamiento a un paciente con neoplasma.
ARP060101829A 2005-05-05 2006-05-05 Composiciones y metodos para el tratamiento de neoplasmas AR053865A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67807805P 2005-05-05 2005-05-05

Publications (1)

Publication Number Publication Date
AR053865A1 true AR053865A1 (es) 2007-05-23

Family

ID=37396884

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101829A AR053865A1 (es) 2005-05-05 2006-05-05 Composiciones y metodos para el tratamiento de neoplasmas

Country Status (14)

Country Link
US (1) US20060264384A1 (es)
EP (1) EP1883407A4 (es)
JP (1) JP2008540455A (es)
KR (1) KR20080013997A (es)
CN (1) CN101217956A (es)
AR (1) AR053865A1 (es)
AU (1) AU2006244199A1 (es)
BR (1) BRPI0611382A2 (es)
CA (1) CA2607260A1 (es)
IL (1) IL186973A0 (es)
MX (1) MX2007013854A (es)
NO (1) NO20075840L (es)
TW (1) TW200716141A (es)
WO (1) WO2006122007A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138123A1 (en) * 2007-05-09 2008-11-20 Thomas David Y Screening assay to identify correctors of protein trafficking defects
US20090069623A1 (en) * 2007-08-21 2009-03-12 Virginia Commonwealth University Intellectual Property Foundation Methods and compositions for treatment or prevention of radiation-induced fibrosis
WO2009029206A1 (en) * 2007-08-24 2009-03-05 Wake Forest University Health Sciences Chemotherapeutic for inducing an msh2-dependent apoptotic pathway
CN101224207A (zh) * 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
GB0723124D0 (en) * 2007-11-26 2008-01-02 Univ Leuven Kath Targeted radiotherapy
EP3692988A3 (en) * 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
FR2934498B1 (fr) * 2008-08-01 2014-08-15 Commissariat Energie Atomique Utilisation d'une forme soluble d'hla-g dans le traitement des proliferations anormales des lymphocytes b.
CA2740099A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
US8716307B2 (en) 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
WO2011031974A1 (en) * 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
EP2576513A1 (en) 2010-06-01 2013-04-10 Biotheryx Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
US20120040914A1 (en) * 2010-08-11 2012-02-16 University Of North Texas Health Science Center At Fort Worth Enhancing effectiveness of glial cancer therapies
TWI449526B (zh) * 2011-02-23 2014-08-21 Uropro Biotech Co Ltd 用於標靶治療之增敏劑、醫藥組合物、套組及用途
TWI472330B (zh) 2011-02-23 2015-02-11 用於癌症治療之增敏劑、套組及用途
CN102526714B (zh) * 2011-08-24 2013-12-25 贵州神奇集团控股有限公司 治疗肿瘤的药物组合物及其制备方法
WO2013049045A1 (en) * 2011-09-27 2013-04-04 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
CN102357100A (zh) * 2011-10-12 2012-02-22 沈阳药科大学 抗肿瘤联合药物
CN103285381B (zh) * 2012-02-22 2015-06-24 贵州神奇集团 核糖核酸酶和斑蝥素的联用
US20140005260A1 (en) * 2012-06-28 2014-01-02 Tri-Service General Hospital Method for inhibiting cancer metastasis by amiodarone
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US9770421B2 (en) * 2013-03-15 2017-09-26 Indanio Bioscience Inc. Uses for idebenone and related benzoquinones in metabolic disorders and other PPAR α/γ related diseases and conditions
CN104146978B (zh) * 2013-05-13 2016-12-28 沈阳药科大学 一种双硫仑肠溶片剂及其制备方法
WO2016062277A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 驱虫药用于制备抗癌医药组合物中的应用
CN104546813A (zh) * 2015-02-09 2015-04-29 南京闻智生物科技有限公司 盐酸马普替林在制备抑制肿瘤细胞转移和扩散的药物中的应用
KR101773244B1 (ko) * 2015-02-27 2017-09-01 이화여자대학교 산학협력단 암로디핀을 포함하는 뇌종양 예방 또는 치료용 약학적 조성물
US9737515B2 (en) * 2015-03-03 2017-08-22 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for inhibiting tumor growth
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
CA2986930C (en) 2015-06-24 2023-09-26 Duke University Chemical modulators of signaling pathways and therapeutic use
CN106310265A (zh) * 2015-06-30 2017-01-11 清华大学 药物组合物及其制备方法和用途
US10864280B2 (en) 2016-06-09 2020-12-15 Der-Yang Tien Nanodroplet compositions for the efficient delivery of anti-cancer agents
EP3534887B1 (en) * 2016-11-03 2023-09-20 UCL Business Ltd Cancer therapy for mixed lineage leukemia
CN108324945B (zh) * 2017-01-19 2020-09-08 首都医科大学附属北京妇产医院 用于抑制纳米药物粒子透过胎盘屏障的抑制剂
CN107616990B (zh) * 2017-06-23 2018-07-13 朱全 吸入式抗肺癌靶向药物制剂
CN108309963A (zh) * 2017-09-14 2018-07-24 中国药科大学 一种用于多抗药性逆转的稳定杂交纳米悬浮剂
CN108218814A (zh) * 2017-12-25 2018-06-29 四川大学 靶向sirt3激动剂及其在aml治疗药物中的应用
JP2021512921A (ja) * 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
CN109316474B (zh) * 2018-11-29 2020-08-11 葛鹏飞 去铁胺在制备预防和/或治疗肿瘤药物中的应用
WO2021007618A1 (en) * 2019-07-17 2021-01-21 Noxopharm Limited Immuno-oncology therapy using isoflavone compounds
KR20210103426A (ko) * 2020-02-13 2021-08-23 (주)프론트바이오 담즙산 또는 이의 유도체, 바이구아나이드 계열 화합물 및 항바이러스제 중 2종 이상을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
CN111514122A (zh) * 2020-05-28 2020-08-11 青岛大学附属医院 双硫仑在制备治疗脂肪肉瘤药物中的应用
TW202214244A (zh) * 2020-08-10 2022-04-16 國立彰化師範大學 具有協同抗癌功效之氯硝柳胺（Ｎｉｃｌｏｓａｍｉｄｅ）和雙硫侖（Ｄｉｓｕｌｆｉｒａｍ）醫藥組合物及其用途
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN112321814B (zh) * 2020-12-30 2021-03-23 广州初曲科技有限公司 一种吉非替尼艾地苯醌轭合物的制备及用途
WO2022252044A1 (en) * 2021-05-31 2022-12-08 Suzhou Singleron Biotechnologies Co., Ltd. Drug repurposing to treat primary lung adenocarcinoma based on deep embeddings of single-cell sequencing analysis
AU2022317139A1 (en) * 2021-07-29 2024-03-14 Lantern Pharma Inc. Treating cancers with combinations of spironolactone and acylfulvenes
CN114601833A (zh) * 2022-04-02 2022-06-10 北京大学口腔医学院 一种治疗肿瘤的化学药物组合
CN117701715A (zh) * 2023-12-20 2024-03-15 东莞市第八人民医院（东莞市儿童医院） Odc1及其抑制剂在乳腺癌他莫昔芬耐药诊断与治疗中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (fr) * 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
CA2492059A1 (en) * 2002-07-11 2004-01-22 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
JP2007500231A (ja) * 2003-05-23 2007-01-11 コンビナトアールエックス インコーポレーティッド 新生物を治療するための併用治療
WO2005000208A2 (en) * 2003-05-30 2005-01-06 Combinatorx, Inc. Combination therapy for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
WO2005027842A2 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms

Also Published As

Publication number Publication date
AU2006244199A1 (en) 2006-11-16
MX2007013854A (es) 2008-01-28
IL186973A0 (en) 2008-06-05
CN101217956A (zh) 2008-07-09
CA2607260A1 (en) 2006-11-16
NO20075840L (no) 2008-01-30
EP1883407A4 (en) 2009-07-01
KR20080013997A (ko) 2008-02-13
JP2008540455A (ja) 2008-11-20
EP1883407A1 (en) 2008-02-06
WO2006122007A1 (en) 2006-11-16
US20060264384A1 (en) 2006-11-23
BRPI0611382A2 (pt) 2010-09-08
TW200716141A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
AR053865A1 (es) Composiciones y metodos para el tratamiento de neoplasmas
CO2020005116A2 (es) Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CR20120202A (es) Métodos y composiciones para tratar cáncer
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
CR9869A (es) Compuestos activos en ppar
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
CR10427A (es) Quinazolinas para la inhibicion de pdk1
ECSP17020133A (es) Derivados de benzodiazepina citotóxicos
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
DK1954274T3 (da) Substituerede quinoloner og fremgangsmåder til anvendelse
CR20110326A (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
BR112015000349A2 (pt) método de tratamento de tumores estromais gastrointestinais
ECSP099398A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con agentes aglutinantes
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
UY32359A (es) Compuestos de plasmalogenos, composiciones farmaceuticas que los contienen y metodos para tratar enfermedades del envejecimiento
ECSP14011792A (es) Inhibidores de iap

Legal Events

Date Code Title Description
FB Suspension of granting procedure